A simple method to cure established tumors by inflammatory killing of normal cells

被引:89
作者
Daniels, GA
Sanchez-Perez, L
Diaz, RM
Kottke, T
Thompson, J
Lai, MY
Gough, M
Karim, M
Bushell, A
Chong, H
Melcher, A
Harrington, K
Vile, RG [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA
[4] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England
[5] Univ London St Georges Hosp, Sch Med, Dept Pathol, London SW17 0RE, England
[6] St James Hosp, CRUK Oncol Unit, Leeds LS9 7TF, W Yorkshire, England
[7] Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England
关键词
D O I
10.1038/nbt1007
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We describe a simple technology used to cure an established metastatic disease. Intradermal injection of plasmid DNA encoding a transcriptionally targeted cytotoxic gene, along with hsp70, not only promoted tissue-specific, inflammatory killing of normal melanocytes, but also induced a CD8(+) T-cell-dependent, antigen-specific response in mice that eradicated systemically established B16 tumors. This CD8(+) T cell response was subsequently suppressed in vivo within a few days. The data demonstrate that deliberate destruction of normal tissue can be exploited to generate immunity against a malignant disease originating from that tissue. This approach obviates the need to identify tumor antigens and does not require complex isolation of tumor cells or their derivatives. In addition, it provides a model system for studying the mechanisms underlying the etiology and control of autoimmune diseases. Finally, despite targeting normal tissue, therapy could be separated from development of overt autoimmune symptoms, suggesting that the strategy may be valuable against tumors derived from both non-essential and essential tissue types.
引用
收藏
页码:1125 / 1132
页数:8
相关论文
共 47 条
[21]  
KEMP EH, 2001, EXPERT REV MOL MED, P1
[22]   Value of tyrosinase RNA detection by an RT-PCR method in melanoma prognosis [J].
Konstantopoulos, K .
BRITISH JOURNAL OF CANCER, 2003, 88 (06) :981-981
[23]   Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses [J].
Kursar, M ;
Bonhagen, K ;
Fensterle, J ;
Köhler, A ;
Hurwitz, R ;
Kamradt, T ;
Kaufmann, SHE ;
Mittrücker, HW .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (12) :1585-1592
[24]  
Linardakis E, 2002, CANCER RES, V62, P5495
[25]   Immune tolerance after delivery of dying cells to dendritic cells in situ [J].
Liu, K ;
Iyoda, T ;
Saternus, M ;
Kimura, Y ;
Inaba, K ;
Steinman, RM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (08) :1091-1097
[26]   HSP70 peptide binding mutants separate antigen delivery from dendritic cell stimulation [J].
MacAry, PA ;
Javid, B ;
Floto, RA ;
Smith, KGC ;
Oehlmann, W ;
Singh, M ;
Lehner, PJ .
IMMUNITY, 2004, 20 (01) :95-106
[27]   Apoptosis or necrosis for tumor immunotherapy: what's in a name? [J].
Melcher, A ;
Gough, M ;
Todryk, S ;
Vile, R .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1999, 77 (12) :824-833
[28]   Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression [J].
Melcher, A ;
Todryk, S ;
Hardwick, N ;
Ford, M ;
Jacobson, M ;
Vile, RG .
NATURE MEDICINE, 1998, 4 (05) :581-587
[29]   Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo [J].
Millar, DG ;
Garza, KM ;
Odermatt, B ;
Elford, AR ;
Ono, N ;
Li, Z ;
Ohashi, PS .
NATURE MEDICINE, 2003, 9 (12) :1469-1476
[30]   Antigen presentation by dendritic cells in vivo [J].
Mougneau, E ;
Hugues, S ;
Glaichenhaus, N .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (08) :1013-1016